Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
85 hedge funds and large institutions have $117M invested in Kezar Life Sciences in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 6 closing their positions.
433% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 6
44% more funds holding
Funds holding: 59 → 85 (+26)
41% more call options, than puts
Call options by funds: $403K | Put options by funds: $286K
35% more capital invested
Capital invested by funds: $86.6M → $117M (+$30.4M)
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.13% less ownership
Funds ownership: 5.2% → 5.07% (-0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.56M |
| 2 |
Millennium Management
New York
|
+$3.67M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$3.65M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$3.03M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$10.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$6.82M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.57M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.56M |
| 5 |
CA
CHI Advisors
New York
|
-$595K |
KZR Hedge Fund Activity: Q2 2020 in Review
85 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q2 2020, worth a combined $117M — up 35% from $86.6M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new KZR positions and 6 closed out — a net gain of 26 holders — while 25 added to existing stakes and 21 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $6.56M. The largest seller was Victory Capital Management, cutting an estimated $10.9M.
- 85 institutional investors held Kezar Life Sciences (KZR) as of Q2 2020, up from 59 in Q1 2020.
- Funds reported $117M of Kezar Life Sciences stock for Q2 2020, up 35% quarter-over-quarter.
- 32 funds opened new Kezar Life Sciences positions in Q2 2020 and 6 closed out, a net change of +26 holders.
- The largest Kezar Life Sciences buyer in Q2 2020 was Cormorant Asset Management, an estimated $6.56M added.
- The largest Kezar Life Sciences seller in Q2 2020 was Victory Capital Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2020.